Better Therapeutics (BTTX) versus The Competition Critical Analysis

Better Therapeutics (NASDAQ:BTTXGet Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it contrast to its rivals? We will compare Better Therapeutics to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Better Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Better Therapeutics’ rivals have a beta of 1.48, meaning that their average share price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Better Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Better Therapeutics 0 0 2 0 3.00
Better Therapeutics Competitors 7 130 274 0 2.65

Better Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 865.52%. As a group, “Health services” companies have a potential upside of 112.07%. Given Better Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Better Therapeutics is more favorable than its rivals.


This table compares Better Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Better Therapeutics N/A -200.73% -114.68%
Better Therapeutics Competitors -325.87% -481.74% -38.64%

Earnings & Valuation

This table compares Better Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Better Therapeutics $10,000.00 -$40.33 million -0.72
Better Therapeutics Competitors $1.36 billion -$98.47 million 29.16

Better Therapeutics’ rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Better Therapeutics beats its rivals on 7 of the 12 factors compared.

About Better Therapeutics

(Get Rating)

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with's FREE daily email newsletter.